Stocks and Investing
Stocks and Investing
Mon, September 9, 2019
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Fri, September 6, 2019
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Matthew Harrison Maintained (VRTX) at Buy with Increased Target to $240 on, Sep 6th, 2019
Matthew Harrison of Morgan Stanley, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Buy with Increased Target from $215 to $240 on, Sep 6th, 2019.
Matthew has made no other calls on VRTX in the last 4 months.
There are 4 other peers that have a rating on VRTX. Out of the 4 peers that are also analyzing VRTX, 1 agrees with Matthew's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Alan Carr of "Needham" Downgraded from Strong Buy to Hold on, Thursday, August 1st, 2019
These are the ratings of the 3 analyists that currently disagree with Matthew
- Edward Tenthoff of "Piper Sandler" Maintained at Buy with Increased Target to $230 on, Thursday, August 1st, 2019
- Evan Seigerman of "Credit Suisse" Maintained at Buy with Increased Target to $213 on, Thursday, August 1st, 2019
- Paul Matteis of "Stifel" Maintained at Strong Buy with Increased Target to $211 on, Thursday, August 1st, 2019